Molecular Weight(MW): 330.74
Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.
Purity & Quality Control
Choose Selective Sodium Channel Inhibitors
|Description||Furosemide is a potent NKCC2 (Na-K-2Cl symporter) inhibitor, used in the treatment of congestive heart failure and edema.|
Furosemide reversibly alters the responses to tones and clicks of the chinchilla basilar membrane in hair cells, causing response-magnitude reductions that are largest (up to 61 dB, averaging 25-30 dB) at low stimulus intensities at the characteristic frequency (CF) and small or nonexistent at high intensities and at frequencies far removed from CF. Furosemide also induces response-phase lags that are largest at low stimulus intensities (averaging 77 degrees) and are confined to frequencies close to CF.  Furosemide concentration- and time-dependently increases the formation of nitric oxide andprostacyclin. Furosemide leads to an enhanced release of kinins into the supernatant of the cells.  Furosemide reversibly suppresses low Ca2+-induced epileptiform activity in hippocampus proper and blocks or significantly reduces different types of epileptiform discharges in the low Mg2+ model and the 4-aminopyridine model.  Furosemide significantly inhibits cell growth in MKN45 cells, but not in MKN28 cells. Furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity. 
|In vivo||Furosemide (0.25 to 2 mg/kg), administered 4 hours before exercise, reduces right atrial pressure (RAP) and pulmonary arterial pressure (PAP) during exercise in dose-dependent manner in horse. |
-  Charak BS, et al. J Antimicrob Chemother,?991, 27(1), 95-104.
-  Wiemer G, et al. J Pharmacol Exp Ther,?994, 271(3), 1611-1615.
-  Gutschmidt KU, et al. Neuroscience,?999, 91(4), 1471-1481.
|In vitro||DMSO||66 mg/mL (199.55 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03730961||Recruiting||Drug: BMS-986231|Drug: Furosemide|Drug: Placebo||Cardiac Failure|Myocardial Failure|Congestive Heart Failure|Heart Decompensation||Bristol-Myers Squibb||November 27 2018||Phase 2|
|NCT03541785||Enrolling by invitation||--||Acute Kidney Injury|Renal Replacement Therapy|Pediatric Intensive Care Units||Children''s Hospital Medical Center Cincinnati|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||July 1 2018||--|
|NCT03573011||Completed||Diagnostic Test: [18F]PSMA-11||Prostate Cancer||University Hospital Ghent||June 15 2018||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.